iPSC Reprogramming & Clinical Differentiation Workbench

1. Somatic Reprogramming

Donor Tissue Source

Delivery Method

Transcription Factor Cocktail

OCT4 SOX2 KLF4 c-MYC NANOG LIN28

Immunogenicity Strategy

Teratoma Safety Purge Gate

2. Cellular Morphology & Fate Kinetics Day 28 (Terminal)

Protocol Day 28

D0-14: Reprogramming D14: Pluripotency D15-28: Directed Lineage D28+: GMP Harvest

Stage: Terminal Dopaminergic Progenitors

Metabolism: OxPhos Reactivated

Colony Density: 1.42 × 10⁶ cells/cm²

Directed Clinical Target Lineage

Morphogen Cascade: Dual SMAD inhibition (Noggin/SB431542) + SHH / CHIR99021 ventral midbrain floor-plate specification -> BDNF/GDNF maturation.

3. Clinical Trial Release Gate

Reprogramming Eff.

1.42%

Target Purity

96.8%

Residual Pluripotent

0.0004%

Viable Doses (Yield)

18 Doses

Quality & Genomic Stability Audits

G-Banding Karyotype & CNV (20q11.21) PASSED (Euploid)

Teratoma Risk Assessment NEGLIGIBLE (<0.001%)

Vector Clearance (Residual Viral RNA) NEGATIVE (0 cp)

Phenotypic Potency & Identity Assay FOXA2+/LMX1A+ >95%

GMP Clinical Release Status

PASSED_STAGE_1_CLEARANCE

Protocol Validation Digest

Ready for batch compilation.